<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2020.1011376</article-id><article-id pub-id-type="publisher-id">ACM-38535</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20201100000_80471309.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  CD40-CD40L信号通路与急性冠脉综合征相关性研究进展
  Research Progress on Relationship between CD40-CD40L Signal Pathway and Acute Coronary Syndrome
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>李</surname><given-names>燕</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>胡</surname><given-names>扬扬</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>陈</surname><given-names>鹏</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>昆明医科大学药学院暨云南省天然药物药理重点实验室，云南 昆明</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>04</day><month>11</month><year>2020</year></pub-date><volume>10</volume><issue>11</issue><fpage>2493</fpage><lpage>2498</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  
    CD40及其免疫调节配体CD40L是一对互补跨膜糖蛋白，分别属于神经生长因子受体(NGFR)/肿瘤坏死因子受体(TNF-R)超家族和肿瘤坏死因子(TNF)超家族成员，参与许多疾病的发生发展过程。研究发现，CD40-CD40L通路不仅与免疫性疾病(自身免疫性疾病和免疫缺陷病)的发展进程密切相关，同时还介导炎症反应，几乎贯穿急性冠状动脉综合征(acute coronary syndrome, ACS)全过程。现就CD40-CD40L通路与急性冠脉综合征的相关性做一简要概述，以期进一步为探讨CD40-CD40L通路与心血管疾病的预防、治疗提供理论依据。
    CD40 and its immunoregulatory ligand (CD40L) are a pair of complementary transmembrane glycoproteins belonging to the nerve growth factor receptor (NGFR)/tumor necrosis factor receptor (TNF-R) superfamily and tumor necrosis factor (TNF) superfamily respectively and participate in the occurrence and development of many diseases. It has been found that CD40-CD40L signal pathway is not only closely related to the development of immune diseases (autoimmune and immune deficiency diseases), but also mediates inflammatory response, almost throughout the whole process of acute coronary syndrome (ACS). In this paper, the interactions between CD40- CD40L pathway and acute coronary syndrome were briefly summarized, to provide more theoretical basis for CD40-CD40L signal pathway and prevention and treatment of cardiovascular diseases. 
  
 
</p></abstract><kwd-group><kwd>急性冠脉综合征，CD40-CD40L信号通路，研究进展, Acute Coronary Syndrome</kwd><kwd> CD40-CD40L Signal Pathway</kwd><kwd> Research Progress</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>CD40及其免疫调节配体CD40L是一对互补跨膜糖蛋白，分别属于神经生长因子受体(NGFR)/肿瘤坏死因子受体(TNF-R)超家族和肿瘤坏死因子(TNF)超家族成员，参与许多疾病的发生发展过程。研究发现，CD40-CD40L通路不仅与免疫性疾病(自身免疫性疾病和免疫缺陷病)的发展进程密切相关，同时还介导炎症反应，几乎贯穿急性冠状动脉综合征(acute coronary syndrome, ACS)全过程。现就CD40-CD40L通路与急性冠脉综合征的相关性做一简要概述，以期进一步为探讨CD40-CD40L通路与心血管疾病的预防、治疗提供理论依据。</p></sec><sec id="s2"><title>关键词</title><p>急性冠脉综合征，CD40-CD40L信号通路，研究进展</p></sec><sec id="s3"><title>Research Progress on Relationship between CD40-CD40L Signal Pathway and Acute Coronary Syndrome</title><p>Yan Li, Yangyang Hu, Peng Chen</p><p>Pharmaceutical College &amp; Key Laboratory of Pharmacology for Natural Products of Yunnan Province, Kunming Medical University, Kunming Yunnan</p><p><img src="//html.hanspub.org/file/10-1571662x4_hanspub.png" /></p><p>Received: Oct. 11<sup>th</sup>, 2020; accepted: Nov. 2<sup>nd</sup>, 2020; published: Nov. 9<sup>th</sup>, 2020</p><p><img src="//html.hanspub.org/file/10-1571662x5_hanspub.png" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>CD40 and its immunoregulatory ligand (CD40L) are a pair of complementary transmembrane glycoproteins belonging to the nerve growth factor receptor (NGFR)/tumor necrosis factor receptor (TNF-R) superfamily and tumor necrosis factor (TNF) superfamily respectively and participate in the occurrence and development of many diseases. It has been found that CD40-CD40L signal pathway is not only closely related to the development of immune diseases (autoimmune and immune deficiency diseases), but also mediates inflammatory response, almost throughout the whole process of acute coronary syndrome (ACS). In this paper, the interactions between CD40- CD40L pathway and acute coronary syndrome were briefly summarized, to provide more theoretical basis for CD40-CD40L signal pathway and prevention and treatment of cardiovascular diseases.</p><p>Keywords:Acute Coronary Syndrome, CD40-CD40L Signal Pathway, Research Progress</p><disp-formula id="hanspub.38535-formula4"><graphic xlink:href="//html.hanspub.org/file/10-1571662x6_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2020 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/10-1571662x7_hanspub.png" /> <img src="//html.hanspub.org/file/10-1571662x8_hanspub.png" /></p></sec><sec id="s5"><title>1. 急性冠脉综合征</title><p>ACS (acute coronary syndrome, ACS)是心源性死亡的主要原因，是一种严重的心血管疾病，严重危害了人类健康 [<xref ref-type="bibr" rid="hanspub.38535-ref1">1</xref>]。每年全世界有1700万人死于心血管疾病，其中ACS约占50%，且发病率逐年上升，已成为城乡居民死亡的首位原因 [<xref ref-type="bibr" rid="hanspub.38535-ref2">2</xref>]。ACS是动脉粥样硬化(atherosclerosis, AS)中的斑块逐渐增大，继而破裂，激活血小板聚集，从而导致血管内血栓形成、冠状动脉阻塞引起的急性心肌缺血综合征，其病理基础在于斑块破裂或侵蚀后冠状动脉血栓形成，造成冠脉不完全或完全闭塞，导致急性心肌缺血 [<xref ref-type="bibr" rid="hanspub.38535-ref3">3</xref>]。</p><p>冠脉粥样斑块破裂是ACS发生的基础，在ACS发生的过程中，破裂的斑块称为易损斑块(vulnerable plaque, VP) [<xref ref-type="bibr" rid="hanspub.38535-ref4">4</xref>]。动脉粥样硬化斑块从无病症期到有病症期的进展取决于其结构和成分，破裂斑块的原型包括一个大的、富含脂质、柔软的核心，并伴有斑块内出血，占斑块体积的一半以上，被一层薄薄的纤维帽所覆盖，炎症细胞浸润严重 [<xref ref-type="bibr" rid="hanspub.38535-ref5">5</xref>]。炎症反应的激活导致斑块的不稳定、破裂继发血栓形成，导致ACS的发生。炎症反应参与ACS全过程，涉及众多的炎症调节分子，如：促炎细胞因子、黏附分子、趋化因子等。除炎症调节分子外，也有大量的浆细胞、T淋巴细胞、C-反应蛋白、巨噬细胞等炎性细胞的产生 [<xref ref-type="bibr" rid="hanspub.38535-ref6">6</xref>]。</p></sec><sec id="s6"><title>2. CD40-CD40L信号通路</title><p>CD40也称为Bp50，是由277个氨基酸组成的I 型跨膜蛋白。胞内、胞外和跨膜区三个部分的氨基酸数目分别为62、193、22。CD40在细胞中的表达十分广泛，造血来源与非造血来源的细胞中均可表达，表皮树突状细胞(dendritic cells, DC)、B淋巴细胞、平滑肌细胞(smooth muscle cell, SMC)、血管内皮细胞(endothelial cells, ECs)、胸腺上皮细胞、成纤维细胞、单核/巨噬细胞 [<xref ref-type="bibr" rid="hanspub.38535-ref7">7</xref>]、星状细胞、滑膜细胞 [<xref ref-type="bibr" rid="hanspub.38535-ref8">8</xref>]、胰岛β细胞、胰腺导管细胞以及血小板 [<xref ref-type="bibr" rid="hanspub.38535-ref9">9</xref>] 都有CD40的表达。CD40的表达在非疾病状态下处于低水平，当受炎症因子或CD40L刺激时，其表达水平显著上升。</p><p>CD40L为CD40的配体，又称gp39、CD154、TNFSF5，是一种II型的跨膜蛋白。1998年，Henn等 [<xref ref-type="bibr" rid="hanspub.38535-ref10">10</xref>] 就已经在血小板、CD40<sup>+</sup>T淋巴细胞以及平滑肌细胞外表面发现CD40L。后又发现CD40L和CD40一样能在多种细胞表面表达，如：自然杀伤细胞(NK)、B淋巴细胞、单核/巨噬细胞、胰岛B细胞、嗜碱性粒细胞、肥大细胞 [<xref ref-type="bibr" rid="hanspub.38535-ref11">11</xref>]。CD40L在体内主要以膜结合型CD40L (membrane bound CD40, mCD40L)和游离状态的可溶性CD40L (soluble CD40L, sCD40L)这两种形式存在。sCD40L由CD40L水解而成，在免疫细胞、血管壁及血小板中都有表达 [<xref ref-type="bibr" rid="hanspub.38535-ref12">12</xref>]。CD40-CD40L信号通路，不仅参与调节免疫反应，也参与了炎症反应的发生发展，并调控了通路上一系列的因子，包括上游因子-CD40、CD40L，下游因子-单核细胞趋化蛋白-1 (monocyte chemoattractant protein-1, MCP-1)、肿瘤坏死因子-α (TNF-α)、白介素-6 (IL-6)、γ-干扰素(IFN-γ)、核转录因子(nuclear factor-kappa B, NF-κB)等。</p></sec><sec id="s7"><title>3. CD40-CD40L信号通路与急性冠脉综合征</title><sec id="s7_1"><title>3.1. 刺激斑块内细胞分泌免疫炎性因子</title><p>AS斑块主要由脂质核心和纤维帽两部分构成，脂质核心的主要构成组分是ECs和巨噬细胞，纤维帽的主要构成组分是活化的T淋巴细胞和SMCs。研究发现，CD40/CD40L与这些细胞产生的炎性反应有极大的关联性 [<xref ref-type="bibr" rid="hanspub.38535-ref13">13</xref>]。CD40/CD40L能够增强巨噬细胞、T淋巴细胞、ECs和SMCs的表达、释放巨噬细胞炎性因子(MIP)1α和1β、IL-8、MCP-1等。这些炎症分子的释放可以招募更多的巨噬细胞和T淋巴细胞到动脉斑块，从而形成更大的斑块。与此同时，T淋巴细胞和巨噬细胞又可以分泌一系列的炎性因子如，IL-2、IL-4、IL-5、IL-12、IL-15、IFN-γ以及TNF-α，还可加强IL-1β转化酶对IL-1β的作用从而增加IL-1β的释放 [<xref ref-type="bibr" rid="hanspub.38535-ref14">14</xref>]。这些组织细胞因子成为炎性反应的强大助推力，导致免疫炎症效应的级联放大，大大加速了AS的恶化。</p></sec><sec id="s7_2"><title>3.2. 吸引更多细胞在斑块内集聚</title><p>有研究表明，当血小板和单核细胞结合后形成血小板-单核细胞结合体，结合后的单核细胞会获得更强的粘附、迁移能力，能够更多的在AS斑块内聚积 [<xref ref-type="bibr" rid="hanspub.38535-ref15">15</xref>]。CD40-CD40L通路可以加强血小板的活化，增加血小板单核细胞复合物数量。Leeuwn等 [<xref ref-type="bibr" rid="hanspub.38535-ref16">16</xref>] 在实验中发现大鼠损伤的部位出现了中性粒细胞，经过研究，证实它在单核细胞炎症反应中作为介质，发挥了强有力的作用 [<xref ref-type="bibr" rid="hanspub.38535-ref17">17</xref>]，有了中性粒细胞的催化，单核细胞的炎症反应更为剧烈，为AS的进一步发展创造了良好的条件。不仅如此，AS斑块内SMCs和巨噬细胞的数目与斑块的严重程度呈正比，而这些细胞与表达CD40L的T细胞存在紧密联系 [<xref ref-type="bibr" rid="hanspub.38535-ref18">18</xref>]。</p></sec><sec id="s7_3"><title>3.3. 抑制基质胶原形成</title><p>基质中的胶原蛋白越多，纤维帽能够承受的拉力就越大，斑块破碎的可能性就越小。AS斑块内存在大量CD4<sup>+ </sup>Th1细胞。CD40/CD40L可诱导CD4<sup>+</sup> Th1细胞分泌IFN-γ， IFN-γ严重抑制SMC中胶原的生成，不利于斑块的稳定 [<xref ref-type="bibr" rid="hanspub.38535-ref19">19</xref>]。</p></sec><sec id="s7_4"><title>3.4. 增加基质金属蛋白酶(MMPs)的表达</title><p>MMPs是一类依赖Zn<sup>2+</sup>、Ca<sup>2+</sup>的内肽酶超家族，来源广泛，可以被体内ECs、SMCs、巨噬细胞、单核细胞、中性粒细胞等多种细胞分泌 [<xref ref-type="bibr" rid="hanspub.38535-ref20">20</xref>]。细胞外基质(extracellular matrix, ECM)是无病变血管壁的主要组成部分，MMPs能降解所有ECM构成组分，是ECM的主要调节物质，在血管ECM重塑中具有重要作用，参与AS中血管重构、引发斑块破裂，其影响血管内斑块易破裂程度与多种炎症因子有关 [<xref ref-type="bibr" rid="hanspub.38535-ref21">21</xref>]。在 MMPs酶的作用下，打破了基质合成与降解之间的均衡，使斑块变得脆弱，斑块由原来的稳定型趋向不稳定型，从而斑块易于破裂。所以，Johnson等 [<xref ref-type="bibr" rid="hanspub.38535-ref22">22</xref>] 提出MMPs是最能反映斑块易损性的生物学指标。研究发现 [<xref ref-type="bibr" rid="hanspub.38535-ref23">23</xref>]，ACS病人比稳定型心绞痛病人有更高水平的sCD40L和MMP-9。CD40/CD40L自身的相互作用也可以诱导AS斑块部位的MMPs的高表达，形成恶性循环，导致易损斑块的破裂。刘全生等 [<xref ref-type="bibr" rid="hanspub.38535-ref24">24</xref>] 研究表明，CD40/CD40L与斑块易损有着极强的关联性，越脆弱的斑块中CD40、CD40L的含量越高 [<xref ref-type="bibr" rid="hanspub.38535-ref24">24</xref>]。另有研究表明CD40/CD40L可以刺激ECs、SMCs、巨噬细胞分泌MMP-1、2、3、9、12系列MMPs因子 [<xref ref-type="bibr" rid="hanspub.38535-ref25">25</xref>]。此外，CD40/CD40L还可以通过激活TNF-α、IL-1等多种炎性因子上调MMPs的活性 [<xref ref-type="bibr" rid="hanspub.38535-ref26">26</xref>]。</p></sec><sec id="s7_5"><title>3.5. 促进斑块内血管新生</title><p>“血管新生”最早是在1787年由英国学者约翰&#183;亨特提出 [<xref ref-type="bibr" rid="hanspub.38535-ref27">27</xref>]，指原有的血管上生成新血管的过程。这些新生的血管仅由单层ECs组成，非常不稳定，一旦斑块内的血管破裂，就会发生出血甚至整个斑块破裂，加重管腔狭小，增加ACS的风险。血管新生的步骤包括蛋白酶的产生、ECs的迁移和增殖、血管的形成、新血管的交融、新基底膜的合成、以及周细胞和SMCs的结合 [<xref ref-type="bibr" rid="hanspub.38535-ref28">28</xref>]。血管新生过程受到许多细胞因子的精密调控，包括血管内皮生长因子(vascular endothelial growth factor, VEGF)、成纤维细胞生长因子(fibroblast growth factor, FGFs)、血管生成素(angiopoietin)、血小板衍生生长因子(platelet-derived growth factor, PDGF)、TNF-α等 [<xref ref-type="bibr" rid="hanspub.38535-ref29">29</xref>]。</p><p>实验结果显示，ECs可以通过CD40-CD40L途径分泌VEGF介导血管新生。还有研究表明巨噬细胞释放的微粒介导的CD40-CD40L也参与了新生血管的形成 [<xref ref-type="bibr" rid="hanspub.38535-ref30">30</xref>]。此外，另有研究发现CD40L诱导IL-15、IL-8以及相关趋化因子的表达也与新生血管的形成有关 [<xref ref-type="bibr" rid="hanspub.38535-ref31">31</xref>]，CD40-CD40L对易损斑块的调控作用如图1所示。</p><p>图1. CD40-CD40L对易损斑块的调控作用</p></sec></sec><sec id="s8"><title>4. 展望</title><p>CD40-CD40L信号通路通过激活免疫炎症反应、促进血栓形成在ACS的发生、发展及预后中有着重要作用，更可能是导致易损斑块破裂的一个中间环节，阻断该通路目前已成为ACS防治的新靶点。但CD40-CD40L系统是机体免疫应答的重要组成部分，长期或完全阻断CD40-CD40L系统是一种严重的免疫抑制，可能导致不良后果，如免疫缺陷和一些不能预估的危害。因此，深入研究CD40-CD40L信号通路促不稳定斑块形成的机制，寻找抑制和调整而非完全阻断CD40-CD40L系统生理功能的途径，可能成为治疗AS和预防ACS安全有效的新方法。</p></sec><sec id="s9"><title>文章引用</title><p>李 燕,胡扬扬,陈 鹏. CD40-CD40L信号通路与急性冠脉综合征相关性研究进展Research Progress on Relationship between CD40-CD40L Signal Pathway and Acute Coronary Syndrome[J]. 临床医学进展, 2020, 10(11): 2493-2498. https://doi.org/10.12677/ACM.2020.1011376</p></sec><sec id="s10"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.38535-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">徐谭, 刘如平, 袁俊强, 等. 急性冠状动脉综合征患者经皮冠状动脉介入术后平均血小板容积对近期预后的影响[J]. 中国动脉硬化杂志, 2020, 28(7): 599-603.</mixed-citation></ref><ref id="hanspub.38535-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">王顺楷, 方志敏, 刘顺民, 等. 循环microRNA-126在急性冠脉综合征患者中的表达差异[J]. 世界最新医学信息文摘, 2019, 19(91): 27+30.</mixed-citation></ref><ref id="hanspub.38535-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">方子寒, 谢盈彧, 张军平. 急性冠状动脉综合征中医诊治概述[J]. 中华中医药学刊, 2019, 37(8): 1852-1855.</mixed-citation></ref><ref id="hanspub.38535-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Moreno, P.R., Purushothaman, K.R., Fuster, V., et al. (2002) Intimomedial Interface Damage and Adventitial Inflammation Is Increased beneath Disrupted Atherosclerosis in the Aorta: Implications for Plaque Vulnerability. Circulation, 105, 2504-2511. &lt;br&gt;https://doi.org/10.1161/01.CIR.0000017265.52501.37</mixed-citation></ref><ref id="hanspub.38535-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Lairez, O. and Hyafil, F. (2020) A Clinical Role of PET in Atherosclerosis and Vulnerable Plaques? Seminars in Nuclear Medicine, 50, 311-318. &lt;br&gt;https://doi.org/10.1053/j.semnuclmed.2020.02.017</mixed-citation></ref><ref id="hanspub.38535-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">徐成斌. 急性冠脉综合征的病理与病理生理学[J]. 中国医刊, 2001, 36(11): 7-9.</mixed-citation></ref><ref id="hanspub.38535-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Cholette, J.M., Blumberg, N., Phipps, R.P., et al. (2008) Developmental Changes in Soluble CD40 Ligand. The Journal of Pediatrics, 152, 50-54. &lt;br&gt;https://doi.org/10.1016/j.jpeds.2007.06.036</mixed-citation></ref><ref id="hanspub.38535-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Geldart, T. and Illidge, T. (2005) Anti-CD40 Monoclonal Antibody. Leukemia &amp; Lymphoma, 46, 1105-1113.  
&lt;br&gt;https://doi.org/10.1080/10428190500085255</mixed-citation></ref><ref id="hanspub.38535-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">杜振兰. CD40-CD40L共刺激途径在体液免疫和细胞免疫中的作用[J]. 细胞与分子免疫学杂志, 2012, 28(12): 1341-1343.</mixed-citation></ref><ref id="hanspub.38535-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Volker, H., Joseph, R.S., Michael, G., et al. (1998) CD40 Ligand on Activated Platelets Triggers an Inflammatory Reaction of Endothelial Cells. Nature, 391, 591-594. &lt;br&gt;https://doi.org/10.1038/35393</mixed-citation></ref><ref id="hanspub.38535-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Danese, S., Sans, M. and Fiocchi, C. (2004) The CD40/CD40L Costimulatory Pathway in Inflammatory Bowel Disease. Gut, 53, 1035-1043. &lt;br&gt;https://doi.org/10.1136/gut.2003.026278</mixed-citation></ref><ref id="hanspub.38535-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">吴辉, 吴伟, 卿立金. CD40/CD40L信号通路与易损斑块关系及中医药干预策略[J]. 中国医师协会中西医结合医师大会, 2011, 23(12): 373-375.</mixed-citation></ref><ref id="hanspub.38535-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Liu, Y.F., Yu, H.M., Zhang, Y., et al. (2008) TLRs Are Important Inflammatory Factors in Atherosclerosis and May Be a Therapeutic Target. Medical Hypotheses, 70, 314-316. &lt;br&gt;https://doi.org/10.1016/j.mehy.2007.05.030</mixed-citation></ref><ref id="hanspub.38535-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Schönbeck, U., Mach, F., Bonnefoy, J.Y., et al. (1997) Ligation of CD40 Activates Interleukin 1beta-Converting Enzyme (Caspase-1) Activity in Vascular Smooth Muscle and Endothelial Cells and Promotes Elaboration of Active Interleukin 1beta. Journal of Biological Chemistry, 272, 19569-19574. &lt;br&gt;https://doi.org/10.1074/jbc.272.31.19569</mixed-citation></ref><ref id="hanspub.38535-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Van, J.M., Da, M.P., Mol, A., et al. (2008) Transendothelial Migration Drives Dissociation of Plateletmonocyte Complexes. Thrombosis and Haemostasis, 100, 271-279. &lt;br&gt;https://doi.org/10.1160/TH08-03-0165</mixed-citation></ref><ref id="hanspub.38535-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Van, L.M., Gijbels, M.J., et al. (2008) Accumulation of Myeloperoxidase-Positive Neutrophils in Atherosclerotic Lesions in LDLR-/-mice. Arteriosclerosis, Thrombosis, and Vascular Biology, 28, 84-89.  
&lt;br&gt;https://doi.org/10.1161/ATVBAHA.107.154807</mixed-citation></ref><ref id="hanspub.38535-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Soehnlein, O., Zernecke, A., Eriksson, E.E., et al. (2008) Neutrophil Secretion Products Pave the Way for Inflammatory Monocytes. Blood, 112, 1461-1471. &lt;br&gt;https://doi.org/10.1182/blood-2008-02-139634</mixed-citation></ref><ref id="hanspub.38535-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Erbel, C., Sato, K., Meyer, F.B., et al. (2007) Functional Profile of Activated Dendritic Cells in Unstable Atherosclerotic Plaque. Basic Research in Cardiology, 102, 123-132. &lt;br&gt;https://doi.org/10.1007/s00395-006-0636-x</mixed-citation></ref><ref id="hanspub.38535-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">朱星. 散结通脉方对动脉粥样硬化大鼠CD40/CD40L信号通路干预的实验研究[D]: [博士学位论文]. 长春: 长春中医药大学, 2019, 204(3): 1246-1352.</mixed-citation></ref><ref id="hanspub.38535-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">朱丹, 赵旭颖, 李海啸, 等. 急性脑梗死患者颈动脉斑块与基质金属蛋白酶、血清白介素及多肽生长因子的关系研究[J]. 现代生物医学进展, 2019, 19(18): 3465-3469+545.</mixed-citation></ref><ref id="hanspub.38535-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">杨雪娜, 熊咏民. 基质金属蛋白酶在骨关节疾病中的研究进展[J]. 国外医学(医学地理分册), 2019, 40(4): 470-474.</mixed-citation></ref><ref id="hanspub.38535-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">Heider, P., Pelisek, J., Poppert, H., et al. (2009) Evaluation of Serum Matrix Metalloproteinases as Biomarkers for Detection of Neurological Symptoms in Carotid Artery Disease. Vascular and Endovascular Surgery, 43, 551-560.  
&lt;br&gt;https://doi.org/10.1177/1538574409334826</mixed-citation></ref><ref id="hanspub.38535-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">李江, 赵水平, 彭道泉, 等. 冠心病患者血清sCD40L和MMP-9的变化及相关性[J]. 中南大学学报(医学版), 2004, 103(5): 517-520.</mixed-citation></ref><ref id="hanspub.38535-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">刘全生, 张雯凌. 可溶性CD40L水平对急性脑梗死患者颈动脉粥样硬化斑块稳定性的影响[J]. 中国实用神经疾病杂志, 2016, 19(7): 12-13.</mixed-citation></ref><ref id="hanspub.38535-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">Lee, J.J. (2007) Matrix Metalloproteinases: Influence on Smooth Muscle Cells and Atherosclerotic Plaque Stability. Expert Review of Cardiovascular Therapy, 5, 265-282. &lt;br&gt;https://doi.org/10.1586/14779072.5.2.265</mixed-citation></ref><ref id="hanspub.38535-ref26"><label>26</label><mixed-citation publication-type="other" xlink:type="simple">刘智敏. 基质金属蛋白酶的结构、功能和调节[J]. 生物医学工程学杂志, 2015(4): 680-683.</mixed-citation></ref><ref id="hanspub.38535-ref27"><label>27</label><mixed-citation publication-type="other" xlink:type="simple">Duran, C.L., Howell, D.W., Dave, J.M., et al. (2017) Molecular Regulation of Sprouting Angiogenesis. Comprehensive Physiology, 8, 153-235. &lt;br&gt;https://doi.org/10.1002/cphy.c160048</mixed-citation></ref><ref id="hanspub.38535-ref28"><label>28</label><mixed-citation publication-type="other" xlink:type="simple">Asghar, F., Ali, S., Houman, K., et al. (2019) Therapeutic Targeting of Angiogenesis Molecular Pathways in Angiogenesis-Dependent Diseases. Biomedicine &amp; Pharmacotherapy, 110, 775-785.  
&lt;br&gt;https://doi.org/10.1016/j.biopha.2018.12.022</mixed-citation></ref><ref id="hanspub.38535-ref29"><label>29</label><mixed-citation publication-type="other" xlink:type="simple">Ribatti, D. (2014) The Discovery of Angiogenic Growth Factors: The Contribution of Italian Scientists. Vascular Cell, 6, 162-170. &lt;br&gt;https://doi.org/10.1186/2045-824X-6-8</mixed-citation></ref><ref id="hanspub.38535-ref30"><label>30</label><mixed-citation publication-type="other" xlink:type="simple">Leroyer, A.S., Pierre-Emmanuel, R., Jean-Sébastien, S., et al. (2008) CD40 Ligand+ Microparticles from Human Atherosclerotic Plaques Stimulate Endothelial Proliferation and Angiogenesis a Potential Mechanism for Intraplaque Neovascularization. Journal of the American College of Cardiology, 52, 1302-1311.  
&lt;br&gt;https://doi.org/10.1016/j.jacc.2008.07.032</mixed-citation></ref><ref id="hanspub.38535-ref31"><label>31</label><mixed-citation publication-type="other" xlink:type="simple">Simonini, A., Moscucci, M., Mulle, D.W.M., et al. (2000) IL-8 Is an Angiogenic Factor in Human Coronary Atherectomy Tissue. Circulation, 101, 1519-1526. &lt;br&gt;https://doi.org/10.1161/01.CIR.101.13.1519</mixed-citation></ref></ref-list></back></article>